Skip to main content
. Author manuscript; available in PMC: 2013 Aug 27.
Published in final edited form as: Oncogene. 2008 Dec;27(0 2):S43–S51. doi: 10.1038/onc.2009.352

Table 1.

Activation of mTORC1 signaling in human cancers

Cancer p4E-BP1 pS6K (T389) pS6 pmTOR (S2448)* N References
Breast 71.9% 58.5% (S235/236) 44.9% 89 (Lin et al., 2005)
41.2% (S65) 42.4% 165 (Zhou et al., 2004)
87.3% (T70) 77.7% 77.7% (S240/244) 103 (Rojo et al., 2007)
Colorectal 82.1% (T37/46) 66.1% 60.7% 56 (Zhang et al., 2009)
40% 69 (Nozawa et al., 2007)
Endometrial 61% (S235/236) 75 (Lu et al., 2008)
Glioblastoma 56% 56 (Chakravarti et al., 2004)
94% 75% 268 (Pelloski et al., 2006)
Hepatocellular Carcinoma 47.7% (S240/244) 86 (Villanueva et al., 2008)
88.3% (S235/236) 528 (Zhou et al., 2009)
Lung Adenocarcinoma 84% (S235/236) 77 (McDonald et al., 2008)
100%
54% high (S235/236)
37 (Conde et al., 2006)
Lymphoma 66% (T70) 66% 66% (S240/244) 66% 29 (Vega et al., 2006)
Melanoma 73% (S235/236) 107 (Karbowniczek et al., 2008)
Ovarian 41.1% (T70) 26.4% 15.5% (S240/244) 129 (Castellvi et al., 2006)
Prostate 90.6% (T70) 71.7% (S235/236) 96.2% 84 (Kremer et al., 2006)
Renal Cell Carcinoma 59% (S235/236) 29 (Robb et al., 2007)
85% (S235/236) 375 (Pantuck et al., 2007)
*

Studies using P-mTOR (S2448) alone were not included, as the functional relevance of this site is unknown.

HHS Vulnerability Disclosure